Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Toft

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|June 13, 2008
Bodylifting: indications, technique and complicationsB M Jones, N J Toft
The Journal of Pathology|August 26, 1998
DNA mismatch repair and colorectal cancerN J Toft, M J Arends
Oncogene|June 29, 2001
Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent mannerO J Sansom, N J Toft, D J Winton, et al.
British Journal of Cancer|December 1, 1993
Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availabilityM J Arends, A H McGregor, N J Toft, et al.
Carcinogenesis|April 7, 2000
In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazineN J Toft, O J Sansom, R A Brookes, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 1999
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestineN J Toft, D J Winton, J Kelly, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|June 13, 2008
Bodylifting: indications, technique and complicationsB M Jones, N J Toft
The Journal of Pathology|August 26, 1998
DNA mismatch repair and colorectal cancerN J Toft, M J Arends
Oncogene|June 29, 2001
Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent mannerO J Sansom, N J Toft, D J Winton, et al.
British Journal of Cancer|December 1, 1993
Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availabilityM J Arends, A H McGregor, N J Toft, et al.
Carcinogenesis|April 7, 2000
In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazineN J Toft, O J Sansom, R A Brookes, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 1999
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestineN J Toft, D J Winton, J Kelly, et al.
Pageof 1